AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03813030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal open flow microperfusion
Description: Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose
Study NCT03813030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Microdialysis
Description: Dermal microdialysis will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose
Study NCT03813030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling in dermal sampling visit
Description: 1 sample is taken pre-dose and 12 samples are taken post-dose.
Study NCT03813030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling in clearance visit
Description: 1 sample is taken pre-dose, 3 samples during intravenous infusion and 13 samples post-dose.
Study NCT00470496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: Given IV
Study NCT00470496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo laser light exposure
Study NCT00470496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgery
Study NCT03205579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video group
Description: Using video for educate cancer pain patients
Study NCT03205579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional group
Description: Face to face cancer pain education by trained nurse
Study NCT03537040 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Method of Levels
Description: Talking Therapy
Study NCT00864240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobex TM (Clobetasol) 0.05% Lotion, single exposure
Description: Subjects received Galderma Laboratories, L.P. formulated products
Study NCT01920802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 5mg BID up to 4 weeks
Study NCT01920802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloperidone
Description: 6 mg BID up to 4 weeks
Study NCT01920802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID up to 4 weeks
Study NCT03624816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: hyaluronic acid dermal filler gel
Study NCT01912755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Description: If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
Study NCT01912755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% articaine with 1:100,000 epinephrine
Description: If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
Study NCT01912755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Description: If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.
Study NCT01912755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Description: If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.
Study NCT02633540 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT Radiation
Description: Radiation to Larynx
Study NCT03048630 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Owner-to-Worker training about reducing chemical exposures in nail salons
Study NCT03048630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Owner-to-Worker training about reducing chemical exposures in nail salons
Study NCT00661583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed
Study NCT02560805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combat virtual reality video clip
Description: Subjects will watch a video clip of combat on a computer screen or wearing video goggles.
Study NCT00661583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab and MMC
Description: Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy
Study NCT00661583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMC
Description: MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.
Study NCT00619957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: one placebo once a week for two years followed by one 35 mg risedronate once a week for two years
Study NCT00619957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years
Study NCT04417257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAU-7b
Description: LAU-7b will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
Study NCT04417257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
Study NCT01906437 — intervention group
Intervention type: DEVICE
Intervention: Cardiac Magnetic Resonance Scan
Description: Cardiac Magnetic Resonance Scan
Study NCT03545139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoMTA nusmile
Description: A new formulation of MTA was developed in which bismuth oxide was omitted.
Study NCT03545139 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: White MTA
Description: Revascularization with Conventional white mineral trioxide aggregate as coronal plug.
Study NCT03182738 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: VIP app without HIV-related symptom strategies.
Description: The control group will receive the VIP app without HIV-related symptom strategies
Study NCT03182738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIP app that delivers HIV-related symptom strategies.
Description: The Intervention group will receive the VIP app that delivers HIV-related symptom strategies
Study NCT01293617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blackberries
Description: 300 g blackberries daily for 5 days
Study NCT01293617 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gelatin
Description: 300 g gelatin per day for 5 days
Study NCT02291211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin HIPEC
Description: Using cisplatin in HIPEC plus oral S-1
Study NCT03663257 — intervention group
Intervention type: DEVICE
Intervention: AneurysmFlow
Description: AneurysmFlow R1.0 is an approved (CE labeled, cleared in US, Canada and Argentina), software tool intended to provide relevant information on the blood flow in a cerebral aneurysm and its parent artery based on angiography. It provides color coded and vector field representation of a digital subtraction angiography (DSA). It can quantify blood flow rates in the artery based on DSA and 3-D Rotational Angiogram (3DRA) data. It can visualize blood flow patterns in an aneurysm based on DSA data. Specifically, it calculates the Mean Aneurysm Flow Amplitude (MAFA) ratio to measure the volumetric flow rate quotient before and after Flow Diverter Stent (FDS) implantation in the region of interest. It is manufactured by Philips Medical Systems B.V., a Philips Healthcare company.
Study NCT00430144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belotecan(CKD-602)
Description: Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
Study NCT04210726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% Hypertonic Saline Bath
Description: 25% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 25%).
Study NCT04210726 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Isotonic Saline Bath
Description: 0.9% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 0.9%).
Study NCT02036229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin cream 0.5%
Description: Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
Study NCT02036229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ivermectin cream 0.5%
Description: Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
Study NCT00083161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 60 mg/m2 IV day 1, every 21 days for 4 cycles.
Study NCT00083161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression
Study NCT00083161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 120 mg/m2 IV days 1-3 OR 120 mg/m2 IV day 1 and 120 mg/m2 by mouth BID days 2-3
Study NCT05383690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED bright light treatment device
Description: Subjects will be instructed to use the bright light treatment device, as early as possible, for 30 minutes each morning. These devices will be equipped with monitoring electronics that will enable us to download their daily degree of use. Participants will also be provided with yellow-tinted blue light blocking glasses and will be instructed to wear them starting 2 hours before bedtime if they are viewing LED or liquid-crystal display screens.
Study NCT03522129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Active Study Drug
Study NCT03522129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active study drug
Study NCT01454076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 2.5 mg
Description: Ixazomib 2.5 mg Capsule B (Cycle 1 only)
Study NCT01454076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg Capsule A
Description: Ixazomib 4 mg Capsule A (Cycle 1 only)
Study NCT01454076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg Capsule B
Description: Ixazomib 4 mg Capsule B (Cycle 2 and beyond )
Study NCT01454076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole 400 mg tablets (Cycle 1 only)
Study NCT01454076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin 600 mg capsule (Cycle 1 only)
Study NCT01454076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500 mg tablets (Cycle 1 only)
Study NCT01454076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg Capsule B
Description: Ixazomib 4 mg Capsule B (Cycle 1 and beyond)
Study NCT01488006 — intervention group
Intervention type: DEVICE
Intervention: Bigliani/Flatow Shoulder System
Description: Primary Total Shoulder Arthroplasty with the Bigliani/Flatow prosthesis
Study NCT03979976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Use of ramipril 10mg/day per 12 weeks. Telephone contact was made in the second and sixth week, to ask about possible side effects and ensure adherence
Study NCT04186611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early occupational therapy
Description: The intervention will be the one usually carried out but earlier and on a daily basis. It will consist of the initial assessment and then positioning and/or carrying out activities of daily living.~The daily duration of the intervention will be about 45 minutes to 1 hour. The overall duration of the intervention will be determined according to the objectives and will be at most equal to the time of stay in the intensive care unit.
Study NCT01535235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Lisinopril 20mg QD x 24 weeks
Study NCT01535235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD x24wks
Study NCT02155400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair Hugger
Description: Forced Air Warming Blanket placed over the body of the patient during surgery
Study NCT02155400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype / Experimental device
Description: Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.
Study NCT02155400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype / Experimental device
Description: Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.
Study NCT03778489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: 10 weeks of high intensity exercise training. 2-3 trainings per week of approx. 40 min.
Study NCT03778489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 10 weeks of high intensity exercise training. 2-3 trainings per week of approx. 40 min.
Study NCT02343692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS guided RFA of cystic tumours of the pancreas
Description: Endoscopic ultrasound guided radiofrequency ablation of pancreatic cysts
Study NCT04352920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
Study NCT01339455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AHSCT
Description: AHSCT Procedure:~1. Mobilization and Harvesting:~   * Cyclophosphamide~  * Rituximab~  * GSCF~  * Dexamethasone~  * Apheresis~2. Conditioning and Infusion (3-4 weeks after Mobilization and Harvesting):~   * Cyclophosphamide~  * MESNA~  * Rabbit ATG~  * Rituximab~  * Methylprednisolone~  * Stem Cell infusion~  * GSCF
Study NCT04525729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.
Study NCT04525729 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: RAS 2410
Description: To evaluate the efficacy and safety of RASi in patients with IgAN.
Study NCT04525729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAS 2410
Description: To evaluate the efficacy and safety of RASi in patients with IgAN.
Study NCT02122627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Colecalciferol 16.800 IU per week
Study NCT02122627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04980131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pointed lotus root regulator and guide template aided PPSF
Description: 20 patients in group C received PPSF with pointed lotus-style regulator
Study NCT04980131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flat ended lotus root regulator and guide template aided PPSF
Description: 20 patients in group B received PPSF with flat ended lotus-style regulator
Study NCT02560805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Handgrip Exercise
Description: Subjects will squeeze a hand dynamometer intermittently.
Study NCT02560805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Description: Subjects' hand will be submerged in cold water (\~0-1°C) up to the wrist for 1 minute.
Study NCT02560805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP)
Description: Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.
Study NCT02560805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus
Study NCT02560805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Subjects will receive Losartan 25 mg once a day orally up to 12 weeks
Study NCT02560805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Subjects will receive Atenolol 25 mg once a day orally up to 12 weeks
Study NCT02665117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Magnesium Citrate (KMgCit)
Description: KMgCit will be administer for 4 months with chlorthalidone.
Study NCT03501056 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer
Description: CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
Study NCT03501056 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT03501056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT04433117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shefabone
Description: Silica-calcium phosphate composite.
Study NCT04433117 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bio-Oss
Description: Xenograft Bone substitute. Bone from animals.
Study NCT03360812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online training resource
Description: Please see information included in the description of the intervention group.
Study NCT04219436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertical mattress suturing technique
Description: vertical mattress suturing technique used for flap closure after esthetic crown lengthening
Study NCT04219436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: figure of eight suturing technique
Description: figure of eight suturing technique used for flap closure after esthetic crown lengthening
Study NCT01118910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vusion
Description: Vusion will be applied to areas of intertrigo
Study NCT00227357 — intervention group
Intervention type: DRUG
Intervention: On-site - buprenorphine/naloxone (Suboxone)
Description: Tablet, sub-lingual, 8/2 mg, 1-3 daily
Study NCT00227357 — intervention group
Intervention type: DRUG
Intervention: Off-site - methadone or no agonist
Study NCT02610985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3-D laparoscopy
Description: 3-D laparoscopy
Study NCT02665117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Chloride (KCl)
Description: KCl will be administer for 4 months with chlorthalidone.
Study NCT02665117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.
Study NCT02610985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-D laparoscopy
Description: 2-D laparoscopy
Study NCT02893345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe@Home Intervention Group
Description: For the 8 training visits, participants may select to work on skills in 2 of 5 activity modules: Improving mobility, balance and strength; Managing health and wellness; Staying On Your Own at Home; Maintaining the home; Getting out in the community. Participants may seek single service rehabilitation, medical, and psychological care as usual.
Study NCT02893345 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Persons can set goals and work on activities with or without a family member as they so choose. Participants may seek single service rehabilitation, medical, and psychological care as usual.